ADC Therapeutics (ADCT) and our partners are committed to confronting cancer with the full potential of its science, bringing unique, targeted therapies and hope to patients and their families.
ZYNLONTA® (Loncastuximab tesirine) is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. For eligible US patients with 3L+ DLBCL who are uninsured or underinsured and need financial support, please visit https://www.advancingpatientsupport.com to learn more about our Patient Assistance Program.
Some patients with serious or life-threatening diseases or conditions may not be eligible for clinical trials and may not have other treatment options available. Under specific circumstances, ADCT may provide access to investigational use of loncastuximab tesirine (Lonca) for individual patients through compassionate use (expanded access).
Please note:
- For HCPs in the United States, please submit requests for Lonca expanded access to ADCT via eap@adctherapeutics.com
- For countries outside of the United States, excluding Greater China, Singapore and Japan, requests for Lonca expanded access should be submitted to our partner, Sobi via their portal at: Managed Access Programmes | Sobi
- For Japan, please submit requests for Lonca expanded access to our partner, Mitsubishi Tanabe Pharma Corporation at: https://www.mt-pharma.co.jp/e/inquiry/business/input.html
Participation in the Expanded Access Program is evaluated on a case-by-case basis and is subject to several important considerations. Access to Lonca is subject to regulatory approval(s) and a benefit-risk assessment by ADCT and our partners. All requests are carefully reviewed to ensure the use of the lonca is medically appropriate and the patient’s safety can be maintained. We are committed to responding to all requests in a timely manner.
ADCT evaluates each request for whether:
- The disease or condition is serious or life-threatening.
- There are adequate alternative therapies or access to available clinical trials.
- Lonca is commercially available and reasonably accessible in the patient’s country (e.g., covered by the patient’s insurance or would otherwise create financial hardship).
- There is scientific evidence to support both the safety and the efficacy of lonca for the use requested and sufficient clinical data are available to identify an appropriate dose.
- The potential benefit to the patient justifies the potential risks of the treatment with the investigational medicine and those potential risks are not unreasonable in the context of the disease or condition to be treated.
- An adequate and appropriate supply of lonca is available.
- The patient and/or their guardian is willing and able to provide informed consent and comply with the safety and monitoring requirements defined by ADCT.